Injection fatigue in relapsing-remitting multiple sclerosis

Injection fatigue and needle aversion are among the underestimated barriers in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Current real-world analyses show a significantly lower persistence of injectable basic therapies compared to oral forms of treatment. At the same time, a prospective cohort study shows that psychological barriers such as fear of injections are an independent determinant of missed doses. Against this background, early identification of corresponding risk patients and consideration of oral treatment alternatives is essential to ensure long-term treatment adherence and thus treatment success.